Meeting
2018 Genitourinary Cancers Symposium
Real-world experience with docetaxel for castration-sensitive prostate cancer from a population-based analysis.
Authors
Jean-Michel Lavoie
British Columbia Cancer Agency - Vancouver Centre, Vancouver, BC, Canada
Jean-Michel Lavoie , Kevin Zou , Daniel Khalaf , Bernhard J. Eigl , Christian K. Kollmannsberger , Joanna Vergidis , Krista Noonan , Muhammad Zulfiqar , Daygen L. Finch , Kim N. Chi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 297)
DOI
10.1200/JCO.2018.36.6_suppl.297
Abstract #
297
Poster Bd #
B8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.
First Author: Umang Swami
Poster
2022 ASCO Genitourinary Cancers Symposium
Evaluation of tumor genomic variants in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide: Protocol of a phase 4 study (CUARTET).
First Author: Hirotsugu Uemura
Poster
2018 ASCO Annual Meeting
A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle Frederick Burgess
Poster
2018 Genitourinary Cancers Symposium
Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: A pooled analysis of castration resistance-free survival and toxicity.
First Author: Joelle Helou